FDA OKs Use of Tool to Predict Patient Response to New Form of Cisplatin in Planned Phase 3 Study
News
The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 ... Read more